logo
London's low-traffic zones ‘cut deaths and injuries by more than a third'

London's low-traffic zones ‘cut deaths and injuries by more than a third'

The Guardian6 days ago
Low-traffic neighbourhoodscut road injuries and deaths by more than a third within their boundaries with no apparent negative safety effect on nearby roads, a study has shown.
Based on comparisons of more than a decade of road casualty statistics between 113 London LTNs and other roads that did not have them, the report's authors found that LTNs were associated with a 35% reduction in all injuries, rising to 37% for deaths and serious injuries.
In absolute terms, the study concluded, this meant that creating the LTNs prevented more than 600 road injuries that would have otherwise taken place, including 100 involving death or serious injury.
On boundary roads, those just outside the LTNs, there was no observable change in the number of casualties.
LTNs aim to make smaller residential streets more friendly for walking, wheeling and cycling by using filters to stop through-traffic by motor vehicles. While they have been used in various forms in the UK for decades and are ubiquitous in many European cities, an expansion in their use from 2020 led to pushback from some politicians and parts of the media.
A common criticism has been that LTNs simply displace traffic to boundary roads, which become more dangerous. However, studies have found a negligible impact on traffic levels and the new paper, published in Injury Prevention, a spin-off from the British Medical Journal, indicates this is the same for deaths and injuries.
Of the 113 LTNs studied, 27 were subsequently taken out. According to analysis by the authors, from Westminster University and the London School of Hygiene & Tropical Medicine, if the LTNs had not been removed there would have been 116 fewer injuries overall, 16 of which involved death or serious injuries.
Across the LTNs as a whole, the authors said, an estimated 613 injuries were prevented, including 100 deaths or serious injuries.
The study involved analysing road casualties from 2012 to 2024 on all so-called road links – a sections of road between two junctions – in London, some of which became part of or a boundary to an LTN, while others did not were treated as a control group.
This allowed the authors to observe changes within LTNs and also compare them with changes on other road links, to take account of separate, longer-term changes in injury rates, including lower traffic levels during Covid.
One phenomenon that was apparent between schemes was that the safety benefits of being within an LTN in outer London seemed notably less than those in inner London. Some outer London schemes have been shown as less successful in reducing overall traffic.
Even with such caveats, the results across a relatively large-scale study give supporters of LTNs the ability to argue that they provably prevent injuries and deaths, as has also been shown to be the case for 20mph speed limits in Wales.
Although modal filters, the technical name for LTNs, have been repeatedly shown to be effective when implemented properly, negative media coverage of the wave of schemes introduced from 2020 prompted a political backlash, with Rishi Sunak's government pledging to clamp down on LTNs.
Sunak's government even commissioned a report on LTNs in the apparent hope it would conclude they did not work. When the report found instead they were mainly popular and effective, it was initially buried.
Dr Jamie Furlong from Westminster University's Active Travel Academy, who led the new study, said its findings should reassure policymakers about the schemes.
He said: 'LTNs have led to considerable reductions in road traffic injuries inside their boundaries for all road users – from pedestrians and cyclists to drivers. At the same time, concerns about nearby main roads becoming more dangerous aren't supported by the evidence.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Child in Liverpool reportedly dies after contracting measles
Child in Liverpool reportedly dies after contracting measles

BreakingNews.ie

timean hour ago

  • BreakingNews.ie

Child in Liverpool reportedly dies after contracting measles

A child in Liverpool has died after contracting measles, it has been reported. According to The Sunday Times newspaper, the child was ill with measles and other health problems and was receiving treatment at the Alder Hey Children's Hospital. Advertisement Measles, an infection that typically starts with cold-like symptoms followed by a rash and sometimes small spots in the mouth, is contagious and can lead to serious problems such as meningitis, blindness and seizures if it spreads to other parts of the body. A statement from the Alder Hey Children's NHS Foundation Trust said: 'To respect patient confidentiality, we can't comment on individual cases. 'We are concerned about the increasing number of children and young people who are contracting measles. Measles is a highly contagious viral illness which can cause children to be seriously unwell, requiring hospital treatment, and in rare cases, death. 'The number of children being treated at Alder Hey for effects and complications of measles is increasing (we have treated 17 since June). Advertisement 'We treat children with a range of conditions and illnesses in our hospital, including those with compromised immunity due to other health issues, making them more susceptible to infections, including measles. 'We can prevent people, including children, from contracting measles through vaccination. Please protect yourself and vulnerable children and young people by ensuring you are fully vaccinated.' The child is believed to be the second to succumb to an acute measles infection in Britain this decade. The news comes amid a decline in the uptake of the measles, mumps and rubella (MMR) vaccine in the UK, as experts said only 84 per cent of five-year-old children in England have had the two doses, with uptake 'much lower' in areas like Liverpool and parts of London. Advertisement A Royal College of Paediatrics and Child Health (RCPCH) report released earlier this month determined uptake of vaccines in the UK has stalled over the last decade and is, in many cases, declining. None of the routine childhood vaccinations have met the target for 95 per cent coverage since 2021, meaning British youngsters are at risk of catching illnesses such as measles, meningitis and whooping cough. The report said while some families are hesitant to vaccinate due to fears about the jabs, many face issues that could be resolved with more support, including difficulties booking and attending appointments and a lack of continuity of care, with many parents seeing a different GP or clinician at each visit.

Labour-led council to ban baby formula adverts
Labour-led council to ban baby formula adverts

Telegraph

time3 hours ago

  • Telegraph

Labour-led council to ban baby formula adverts

A Labour-led council is set to ban baby formula companies from advertising its products on sites it owns. Knowsley council in Merseyside made the move as part of its wider plans to prevent the marketing of what it described as 'health harming' products. Last year, the local authority announced it would restrict adverts for unhealthy food on its sites as part of a strategy to tackle obesity rates. A report commissioned by the council has said baby formula should also be included because it is often marketed in a way that suggests it is a better alternative to breastfeeding, BBC News reported. The Advertising Standards Authority, the UK's advertising regulator, prohibits the marketing of baby formula for children under six months – but companies are able to advertise follow-on milks. This proposed ban would go even further by extending it to all baby formula – not just products for children up to a specific age. The World Health Organisation recommends mothers breastfeed their children for the first six months and continue to do so alongside solid foods until a child is at least two years old as best practice. The council's report said: 'Infant formula is often marketed in such a way it suggests its benefits outweigh breastfeeding or simply using cows' milk after the age of one. 'The marketing and packaging of these products can be misleading and undermines public health messaging for breastfeeding, widening health inequalities particularly for those on lower incomes.' The report also proposed similar restrictions on baby foods – typically sold in pouches – because they too, it claimed, are made out to be healthier alternatives to food prepared at home in raw form. It said the food was 'often less nutritious' than prepared foods at home. More than two-thirds of UK babies are given at least some formula milk within two months of birth, official statistics show. However, prices have surged in recent years due to rapid growth in demand and issues with global supply chains. In February 2024, the Competition and Markets Authority launched an investigation into the baby formula market as it sought to address why prices had risen by 25 per cent in just two years. Demand has risen even more acutely for special types of baby formula – including lactose-free versions – but experts have warned against babies without the particular allergies from consuming the product. Dr Vicky Sibson, head of charity First Steps Nutrition, wrote in a paper published in August 2024 that without a cow's milk allergy, babies who consume lactose-free formulas are more likely to gain too much weight or have tooth decay, as the natural milk sugar lactose is replaced with more unhealthy sugars.

What is chikungunya? How to avoid debilitating virus while on holiday as cases rise in France
What is chikungunya? How to avoid debilitating virus while on holiday as cases rise in France

The Independent

time3 hours ago

  • The Independent

What is chikungunya? How to avoid debilitating virus while on holiday as cases rise in France

Health officials are warning travellers of a mosquito-borne virus that can cause debilitating joint pain, after cases emerged in areas of France. While the virus known as chikungunya is more commonly found in tropical areas of the world, cases have now been appeared in France, a popular holiday destination for Brits, especially during the summer months. This year so far, France has reported 14 cases of chikungunya virus, on the mainland and the French island of Corsica. While Europe is not currently experiencing a severe outbreak, health officials on the continent are making travellers aware of the virus as well as the rollout of a new vaccine in the UK. We have rounded up what travellers need to know about the virus, plus advice from a specialist travel doctor on how to best prepare for travelling overseas. What is chikungunya and how is it spread? Chikungunya virus disease is a mosquito-borne disease that is found across tropical and sub-tropical regions. It is spread to humans by a bite from an infected mosquito. It cannot be passed from human to human. Most cases have been found in the Americas, Africa and Asia. Brazil has the most cases, with over 141,000, followed by Argentina with over 2,500 so far in 2025. In total, there have been approximately 220,000 chikungunya cases and 80 related deaths across 14 countries/territories since the beginning of the year. Réunion and Mayotte, two French islands off the east coast of Africa, have ongoing outbreaks of chikungunya, with the former recording 51,000 cases as of May 2025. Mayotte has seen 560 cases, with the island moved to the epidemic phase, which indicates intense and widespread transmission of the virus throughout the territory. The transmission of dengue and chikungunya virus in mainland Europe has been linked by the European Centre for Disease Prevention and Control (ECDC) to travellers who have caught the virus outside the region, then gone to countries within Europe with mosquitoes that are able to carry the virus after biting the person. 'The risk of locally acquired chikungunya and dengue virus transmissions is therefore increasing,' the ECDC said. What are the symptoms? 'Chikungunya' comes from a word used by the Makonde people in Tanzania, where the disease was first discovered in the 1950s, which means 'that which bends up'. This describes the contorted posture of infected people who experience severe joint pain. Alongside joint pain, people can also experience an abrupt onset of fever, joint swelling, muscle pain, headaches, nausea, fatigue and rashes. The joint pain can be debilitating and usually lasts for a few days, but it has been known to last for weeks, months or even years. If an infected person does not experience joint pain, the symptoms will be mild and can go unrecognised as chikungunya. Most people will recover fully from the infection. There have been some occasional cases of eye, heart, and neurological complications, while newborns and older people with underlying medical conditions are at a higher risk of severe disease. Patients with severe disease should be hospitalised because of the risk of organ damage or death. Once someone has recovered from chikungunya, they are likely to be immune to future chikungunya infections. Is there a vaccine? The UK government has approved a vaccine against chikungunya disease, containing a form of the virus that has been weakened so it cannot multiply. The vaccine works by training the immune system to recognise the virus, which will then produce specific antibodies to attack it. It can only be obtained via a prescription and given to those who plan to travel abroad where the virus is present. Last month, the government released a further announcement to say that the Commission on Human Medicines has temporarily restricted the use of the vaccine in people aged 65 and over as a precautionary measure. To prevent getting bitten by mosquitoes, the World Health Organisation advises using insecticides; wearing clothing that minimises skin exposure; using window and door screens, and insecticide-treated mosquito nets; and applying certain repellants to skin and clothing. A travel doctor's guide on being prepared Dr Richard Dawood, a travel medical specialist at Fleet Street Clinic, explained to The Independent how the vaccination can help travellers prevent getting sick from the chikungunya virus. He said: 'This is a new situation for us. Until a very short time ago, we had no vaccine, and the only approach to prevention was to make careful use of insect repellents and insect precautions. 'So now we've got this extra tool in the armoury, and because the vaccine gives long-lasting protection, it's something that could be considered if you are planning to travel over a period of time. 'It's a fairly expensive vaccine, but if you're going to be travelling over a period of years to Southern Europe and beyond, it may be something that could be considered.' When asked about getting the vaccination for a trip to France, Mr Dawood advised to look at the decision in terms of where you will be travelling over the next few years rather than in the context of a single trip. 'The risk from a one-off short trip to France is probably very small,' he said. 'There's been only a very small number of cases so far. So statistically, you're not very likely to, but over time, as somebody who loves to travel and loves going to hot countries, then I would probably want to be protected against it in the long term.' Wherever you are travelling, Mr Dawood advised holidaymakers to 'do your homework'. He said: 'If there's an actual outbreak at your destination, then I would say no hesitation, definitely have the vaccine. 'Taking a bit of time and getting some really focused travel health advice for your particular trip is very worthwhile because it can save you from getting a vaccine that you don't need or that may not be sensible for you, and it can help prioritise the really important things for your trip.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store